Clinical Trial Update: Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing mesoglycan (Prisma) to placebo for secondary prevention of superficial venous thrombosis of the leg has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Superficial Venous Thrombosis

Drugs mentioned

• Prisma (mesoglycan)

Snippet

Sponsor: Quovadis Associazione | Conditions: Superficial Venous Thrombosis of Leg, Secondary Prevention | Phase 2 | Status: COMPLETED